4,4-二乙氧基哌啶 | 52534-66-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4,4-二乙氧基哌啶
• 英文名称: 4,4-diethoxypiperidine
• 英文别名: 4,4-diethoxy-piperidine；4,4-Diethoxypiperidin
• CAS: 52534-66-4
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: WADUXZSSTOYQLD-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C
• 沸点：
  101-102 °C(Press: 20 Torr)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4,4-二乙氧基哌啶 在 盐酸 、 3 A molecular sieve 、 sodium cyanoborohydride 作用下， 以 甲醇 、 正丁醇 为溶剂， 反应 31.0h， 生成 S 9788
  参考文献：
  名称：

  New triazine derivatives as potent modulators of multidrug resistance

  摘要：

  A series of 70 triazine derivatives have been synthesized and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity. Among the 12 selected compounds, 16 (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5-mu-M in DC-3F/AD and KB-A1 cells, respectively) and induced a strong accumulation of adriamycin. The relationship between the increase of ADR accumulation and the fold reversal induced by these compounds and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the P-glycoprotein (Pgp) catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators. In vivo, in association with the antitumor drug vincristine (0.25 mg/kg), 16 (100 mg/kg) increased the TIC by 39% in mice bearing the resistant tumor cell line P388/VCR. According to these interesting properties, 16 was selected for a clinical development because it was more bioavailable than 34, even though it was less active.

  DOI：

  10.1021/jm00091a017
• 作为产物：
  描述：

  1-benzyl-4,4-diethoxypiperidine 在 10 wt% Pd(OH)2 on carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 16.0h， 生成 4,4-二乙氧基哌啶
  参考文献：
  名称：

  Cationic lipids for oligonucleotide delivery

  摘要：

  本发明提供了一种新型的阳离子脂质，可与其他脂质组分如胆固醇和PEG-脂质结合，形成与寡核苷酸一起的脂质纳米粒子。本发明的目的是提供一种易受水解不稳定性影响的阳离子脂质支架，可能导致减少肝脏滞留时间和减少肝细胞毒性。本发明采用缩醛和缩酮来提供对低pH敏感的化学处理，以进行降解。

  公开号：

  US09670487B2

文献信息

• Trisubstituted triazines
  申请人：Adir et Compagnie

  公开号：US05238936A1

  公开（公告）日：1993-08-24

  The compounds are trisubstituted triazines and pyrimidines useful for the suppressing the resistance of tumour cells to anti-cancer agents and for suppressing the resistance of parasites to anti-parasitic agents. A compound disclosed is 2,4-diallylamino-6-4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl) methylamino]piperidin-1-yl}-1,3,5-triazine.

  这些化合物是三取代三嗪和嘧啶，可用于抑制肿瘤细胞对抗癌药物的耐药性以及抑制寄生虫对抗寄生虫药物的耐药性。其中一种化合物是2,4-二烯丙基氨基-6-4-[(10,11-二氢-5H-二苯并[a,d]环庚烯-5-基)甲基氨基]哌啶-1-基}-1,3,5-三嗪。
• 一种利福霉素-硝基咪唑偶联分子的制备方法
  申请人：丹诺医药（苏州）有限公司

  公开号：CN105037389B

  公开（公告）日：2017-09-05

  本发明揭示了一种利福霉素‑硝基咪唑偶联分子的制备方法。本发明的制备方法以甲硝唑为原料，通过改变合成路线，克服了反应条件必须控制在低温条件下的缺陷，并且提高了目标产物的收率。
• [EN] 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES<br/>[FR] BACTÉRICIDES À BASE DE 6,7-DIHYDROIMIDAZO [2,1-B][1,3] OXAZINE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2012141338A1

  公开（公告）日：2012-10-18

  The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): or a salt thereof, wherein R1 represents tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydrobenzoazepinyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolinyl, naphthyl, quinolyl, phenyl, biphenylyl, or pyridyl, these groups being optionally substituted, the phenyl, biphenylyl, and pyridyl represented by R1 each being substituted directly or via a linker with at least one group selected from the group consisting of tetrahydropyridyl, diazepanyl, diazabicycloheptanyl, tetrahydrotriazolopyrazinyl, tetrahydroimidazopyrazinyl, azabicyclooctanyl, oxazolyl, piperazinyl, piperidyl, thiazolyl, and the like, each of these groups being optionally substituted; and R2 represents hydrogen or lower alkyl. The present invention further provides a pharmaceutical composition containing the above.

  本发明提供了一种新型的6,7-二氢咪唑[2,1-b][1,3]噁嗪化合物，该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型抗酸杆菌具有优异的杀菌作用。具体而言，本发明提供了一种由式(1)表示的化合物或其盐，其中R1代表四氢异喹啉基、四氢喹啉基、四氢苯并氮杂环庚基、苯并噁唑基、苯并噻唑基、吲哚基、异吲哚啉基、萘基、喹啉基、苯基、联苯基或吡啶基，这些基团可选地被取代，其中R1表示的苯基、联苯基和吡啶基通过连接基直接或经过至少一种从四氢吡啶基、二氮杂环庚基、二氮杂双环庚基、四氢三唑吡嗪基、四氢咪唑吡嗪基、氮杂双环辛基、噁唑基、哌嗪基、哌啶基、噻唑基等基团中选取的至少一种基团进行取代，这些基团可选地被取代；R2代表氢或低碳基。本发明还提供了包含上述化合物的药物组合物。
• Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof
  申请人：WISSNER Allan

  公开号：US20080293712A1

  公开（公告）日：2008-11-27

  The present invention relates to Benzo[c][2,7]naphthyridine Derivatives, compositions comprising an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for treating or preventing a proliferative disorder or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a Benzo[c][2,7]naphthyridine Derivative, methods for modulating PDK-1 activity, PKA activity, Akt activity, S6K activity, or PKC activity, comprising administering to a subject in need thereof an effective amount of a Benzo[c][2,7]naphthyridine Derivative. The invention also relates to processes for preparing a Benzo[c][2,7]naphthyridine Derivative.

  本发明涉及苯并[c][2,7]萘啉衍生物，包含有效量苯并[c][2,7]萘啉衍生物的组合物，用于治疗或预防增殖性疾病或自身免疫疾病的方法，包括向需要治疗的受体内给予有效量的苯并[c][2,7]萘啉衍生物，用于调节PDK-1活性、PKA活性、Akt活性、S6K活性或PKC活性的方法，包括向需要治疗的受体内给予有效量的苯并[c][2,7]萘啉衍生物。本发明还涉及制备苯并[c][2,7]萘啉衍生物的过程。
• Novel Cationic Lipids for Oligonucleotide Delivery
  申请人：Colletti Steven L.

  公开号：US20130053572A1

  公开（公告）日：2013-02-28

  The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that is susceptible to hydrolytic instability that may translate into reduced liver residence times and reduced hepatocellular toxicity. The present invention employs acetals and ketals to provide a low pH sensitive chemical handle for degradation.

  本发明提供了一种新型阳离子脂质体，可与其他脂质成分（如胆固醇和PEG脂质体）结合，形成含寡核苷酸的脂质纳米粒子。本发明的目的是提供一种易于水解的阳离子脂质体支架，可能导致减少肝脏滞留时间和减少肝细胞毒性。本发明采用缩醛和缩酮来提供低pH敏感的化学手柄进行降解。